These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 30102724)
1. A new biomarker candidate for spinal muscular atrophy: Identification of a peripheral blood cell population capable of monitoring the level of survival motor neuron protein. Otsuki N; Arakawa R; Kaneko K; Aoki R; Arakawa M; Saito K PLoS One; 2018; 13(8):e0201764. PubMed ID: 30102724 [TBL] [Abstract][Full Text] [Related]
2. Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy Controls. Czech C; Tang W; Bugawan T; Mano C; Horn C; Iglesias VA; Fröhner S; Zaworski PG; Paushkin S; Chen K; Kremer T PLoS One; 2015; 10(10):e0139950. PubMed ID: 26468953 [TBL] [Abstract][Full Text] [Related]
3. A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls. Wadman RI; Stam M; Jansen MD; van der Weegen Y; Wijngaarde CA; Harschnitz O; Sodaar P; Braun KP; Dooijes D; Lemmink HH; van den Berg LH; van der Pol WL PLoS One; 2016; 11(11):e0167087. PubMed ID: 27893852 [TBL] [Abstract][Full Text] [Related]
4. SMN Blood Levels in a Porcine Model of Spinal Muscular Atrophy. Iyer CC; Wang X; Renusch SR; Duque SI; Wehr AM; Mo XM; McGovern VL; Arnold WD; Burghes AH; Kolb SJ J Neuromuscul Dis; 2017; 4(1):59-66. PubMed ID: 28269795 [TBL] [Abstract][Full Text] [Related]
5. A novel evaluation method of survival motor neuron protein as a biomarker of spinal muscular atrophy by imaging flow cytometry. Arakawa M; Arakawa R; Tatsumi S; Aoki R; Saito K; Nomoto A Biochem Biophys Res Commun; 2014 Oct; 453(3):368-74. PubMed ID: 25264200 [TBL] [Abstract][Full Text] [Related]
6. Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy. Alves CRR; Zhang R; Johnstone AJ; Garner R; Eichelberger EJ; Lepez SDSD; Yi V; Stevens V; Poxson R; Schwartz R; Zaworski P; Swoboda KJ Muscle Nerve; 2020 Sep; 62(3):351-357. PubMed ID: 32511765 [TBL] [Abstract][Full Text] [Related]
7. A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy. Vezain M; Saugier-Veber P; Melki J; Toutain A; Bieth E; Husson M; Pedespan JM; Viollet L; Pénisson-Besnier I; Fehrenbach S; Bou J; Frébourg T; Tosi M Eur J Hum Genet; 2007 Oct; 15(10):1054-62. PubMed ID: 17609673 [TBL] [Abstract][Full Text] [Related]
8. Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy. Sun Y; Grimmler M; Schwarzer V; Schoenen F; Fischer U; Wirth B Hum Mutat; 2005 Jan; 25(1):64-71. PubMed ID: 15580564 [TBL] [Abstract][Full Text] [Related]
9. [Effect of valproic acid on SMN protein level in peripheral blood mononuclear cells of patients with spinal muscular atrophy and different SMN2 copy numbers]. Sokolik VV; Koliada AK; Shatilo AV Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):53-6. PubMed ID: 25042492 [TBL] [Abstract][Full Text] [Related]
10. Therapeutics development for spinal muscular atrophy. Sumner CJ NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261 [TBL] [Abstract][Full Text] [Related]
11. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog. Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872 [TBL] [Abstract][Full Text] [Related]
12. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Farooq F; Abadía-Molina F; MacKenzie D; Hadwen J; Shamim F; O'Reilly S; Holcik M; MacKenzie A Hum Mol Genet; 2013 Sep; 22(17):3415-24. PubMed ID: 23656793 [TBL] [Abstract][Full Text] [Related]
13. A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy. Nguyen thi Man ; Humphrey E; Lam LT; Fuller HR; Lynch TA; Sewry CA; Goodwin PR; Mackenzie AE; Morris GE Neurology; 2008 Nov; 71(22):1757-63. PubMed ID: 18633133 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy. Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466 [TBL] [Abstract][Full Text] [Related]
15. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033 [TBL] [Abstract][Full Text] [Related]
16. SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Sumner CJ; Kolb SJ; Harmison GG; Jeffries NO; Schadt K; Finkel RS; Dreyfuss G; Fischbeck KH Neurology; 2006 Apr; 66(7):1067-73. PubMed ID: 16481599 [TBL] [Abstract][Full Text] [Related]